SI1276738T1 - 2-amino-3-(alkil)-pirimidonski derivati kot inhibitorji GSK3 beta - Google Patents

2-amino-3-(alkil)-pirimidonski derivati kot inhibitorji GSK3 beta

Info

Publication number: SI1276738T1
Authority: SI; Slovenia
Prior art keywords: gsk3; inhibitors; beta; amino; alkyl
Prior art date: 2000-03-23

Application number

SI200130806T

Other languages

English (en)

Inventor

Garcia Antonio Almario

Ryoichi Ando

Keiichi Aritomo

Jonathan Frost

Adrien Tak Li

Aya Shoda

Fumiaki Uehara

Kazutoshi Watanabe

Original Assignee

Sanofi Aventis

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-23

Filing date

2001-03-22

Publication date

2008-06-30

2001-03-22 Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis

2008-06-30 Publication of SI1276738T1 publication Critical patent/SI1276738T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SI200130806T 2000-03-23 2001-03-22 2-amino-3-(alkil)-pirimidonski derivati kot inhibitorji GSK3 beta SI1276738T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP00400800A EP1136482A1 (en)	2000-03-23	2000-03-23	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
PCT/EP2001/003640 WO2001070729A1 (en)	2000-03-23	2001-03-22	2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
EP01959921A EP1276738B8 (en)	2000-03-23	2001-03-22	2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors

Publications (1)

Publication Number	Publication Date
SI1276738T1 true SI1276738T1 (sl)	2008-06-30

Family

ID=8173604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200130806T SI1276738T1 (sl)	2000-03-23	2001-03-22	2-amino-3-(alkil)-pirimidonski derivati kot inhibitorji GSK3 beta

Country Status (16)

Country	Link
US (2)	US6844335B2 (sl)
EP (2)	EP1136482A1 (sl)
JP (1)	JP4778657B2 (sl)
KR (1)	KR100820543B1 (sl)
CN (2)	CN1247567C (sl)
AR (1)	AR028280A1 (sl)
AT (1)	ATE380806T1 (sl)
AU (1)	AU2001281487A1 (sl)
CA (1)	CA2401241C (sl)
CY (1)	CY1107236T1 (sl)
DE (1)	DE60131844T2 (sl)
DK (1)	DK1276738T3 (sl)
ES (1)	ES2296783T3 (sl)
PT (1)	PT1276738E (sl)
SI (1)	SI1276738T1 (sl)
WO (1)	WO2001070729A1 (sl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR023052A1 (es)	1998-09-25	2002-09-04	Mitsuharu Yoshimura Milton	Derivados de pirimidona
EP1136482A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
SE518184C2 (sv)	2000-03-31	2002-09-03	Perstorp Flooring Ab	Golvbeläggningsmaterial innefattande skivformiga golvelement vilka sammanfogas med hjälp av sammankopplingsorgan
CN1197621C (zh)	2000-04-26	2005-04-20	卫材株式会社	促进排便的药物组合物
AR043700A1 (es)	2001-09-21	2005-08-10	Mitsubishi Pharma Corp	Derivados de 3-substituida-4-pirimidona
ES2323576T3 (es) *	2001-09-21	2009-07-21	Mitsubishi Tanabe Pharma Corporation	Derivados de 4-pirimidona 3-sustituida.
TW201041580A (en) *	2001-09-27	2010-12-01	Alcon Inc	Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
TWI301834B (en)	2001-10-22	2008-10-11	Eisai R&D Man Co Ltd	Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (sl)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
ZA200505258B (en) *	2002-12-16	2006-09-27	Mitsubishi Pharma Corp	3-Substituted-4-pyrimidone derivatives
EP1460076A1 (en) *	2003-03-21	2004-09-22	Sanofi-Synthelabo	Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1460075A1 (en) *	2003-03-21	2004-09-22	Sanofi-Synthelabo	Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
TWI357408B (en)	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives
AU2004265341A1 (en)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005076854A2 (en) *	2004-02-04	2005-08-25	Smithkline Beecham Corporation	Pyrimidinone compounds useful as kinase inhibitors
WO2005095381A1 (en)	2004-03-15	2005-10-13	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP5033624B2 (ja) *	2004-07-09	2012-09-26	エージェンシーフォーサイエンス，テクノロジーアンドリサーチ	ＧＳＫ−３βの変更および増殖性疾患の治療方法
AR050865A1 (es)	2004-09-09	2006-11-29	Sanofi Aventis	Derivados de 2- morfolino-4-pirimidona
US8129377B2 (en) *	2004-09-29	2012-03-06	Mitsubishi Tanabe Pharma Corporation	6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
US20080207594A1 (en)	2005-05-04	2008-08-28	Davelogen Aktiengesellschaft	Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
US7678363B2 (en)	2005-08-26	2010-03-16	Braincells Inc	Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
PL1942898T5 (pl)	2005-09-14	2014-10-31	Takeda Pharmaceuticals Co	Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh)	2005-09-16	2012-09-19	武田药品工业株式会社	用于制备嘧啶二酮衍生物的方法中的中间体
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
TW200813015A (en) *	2006-03-15	2008-03-16	Mitsubishi Pharma Corp	2-(cyclic amino)-pyrimidone derivatives
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
AU2007287319A1 (en) *	2006-08-23	2008-02-28	Pfizer Products Inc.	Pyrimidone compounds as GSK-3 inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
AR076014A1 (es) *	2009-04-02	2011-05-11	Sanofi Aventis	Derivados de 3- (1,4) oxazepan -4-pirimidona
JP5442852B2 (ja)	2009-08-13	2014-03-12	田辺三菱製薬株式会社	タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
JP5535310B2 (ja)	2009-08-13	2014-07-02	田辺三菱製薬株式会社	タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
JP2017524739A (ja)	2014-07-17	2017-08-31	アンセルムＩｎｓｅｒｍ	神経筋接合部関連疾患の処置方法
WO2016207366A1 (en)	2015-06-26	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of viral infections
WO2018217766A1 (en)	2017-05-22	2018-11-29	Whitehead Institute For Biomedical Research	Kcc2 expression enhancing compounds and uses thereof
WO2025215108A1 (en) *	2024-04-10	2025-10-16	Universitat De Barcelona	DUAL G9A/GSK-3ß INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4935631B1 (sl)	1970-12-28	1974-09-25
JPS4935633B1 (sl)	1970-12-30	1974-09-25
JPS559099B2 (sl) *	1972-08-07	1980-03-07
JPS4935633A (sl)	1972-08-09	1974-04-02
US4460589A (en) *	1980-10-03	1984-07-17	The Upjohn Company	Process for treating hypertension
TW229142B (sl) *	1992-04-15	1994-09-01	Nissan Detrochem Corp
US6153618A (en) *	1996-10-11	2000-11-28	Chiron Corporation	Inhibitors of glycogen synthase 3 kinase
BR9713863A (pt) *	1996-12-05	2000-03-14	Amgen Inc	Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
JP2002514195A (ja) *	1996-12-05	2002-05-14	アムジエン・インコーポレーテツド	置換ピリミジン化合物およびそれの使用
AR023052A1 (es) *	1998-09-25	2002-09-04	Mitsuharu Yoshimura Milton	Derivados de pirimidona
EP1136482A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors

2000
- 2000-03-23 EP EP00400800A patent/EP1136482A1/en not_active Withdrawn
2001
- 2001-03-22 EP EP01959921A patent/EP1276738B8/en not_active Expired - Lifetime
- 2001-03-22 AT AT01959921T patent/ATE380806T1/de active
- 2001-03-22 PT PT01959921T patent/PT1276738E/pt unknown
- 2001-03-22 KR KR1020027012431A patent/KR100820543B1/ko not_active Expired - Fee Related
- 2001-03-22 WO PCT/EP2001/003640 patent/WO2001070729A1/en not_active Ceased
- 2001-03-22 CN CNB018069916A patent/CN1247567C/zh not_active Expired - Fee Related
- 2001-03-22 DK DK01959921T patent/DK1276738T3/da active
- 2001-03-22 ES ES01959921T patent/ES2296783T3/es not_active Expired - Lifetime
- 2001-03-22 JP JP2001568932A patent/JP4778657B2/ja not_active Expired - Fee Related
- 2001-03-22 AU AU2001281487A patent/AU2001281487A1/en not_active Abandoned
- 2001-03-22 US US10/221,598 patent/US6844335B2/en not_active Expired - Fee Related
- 2001-03-22 DE DE60131844T patent/DE60131844T2/de not_active Expired - Lifetime
- 2001-03-22 SI SI200130806T patent/SI1276738T1/sl unknown
- 2001-03-22 CN CNA2006100061354A patent/CN1891220A/zh active Pending
- 2001-03-22 CA CA2401241A patent/CA2401241C/en not_active Expired - Fee Related
- 2001-03-23 AR ARP010101372A patent/AR028280A1/es active IP Right Grant
2005
- 2005-01-13 US US11/035,264 patent/US7378413B2/en not_active Expired - Fee Related
2008
- 2008-03-07 CY CY20081100270T patent/CY1107236T1/el unknown

Also Published As

Publication number	Publication date
EP1276738B1 (en)	2007-12-12
EP1276738B8 (en)	2008-02-20
ES2296783T3 (es)	2008-05-01
DE60131844D1 (de)	2008-01-24
JP4778657B2 (ja)	2011-09-21
JP2003528095A (ja)	2003-09-24
US20050130998A1 (en)	2005-06-16
EP1136482A1 (en)	2001-09-26
WO2001070729A1 (en)	2001-09-27
AR028280A1 (es)	2003-04-30
DK1276738T3 (da)	2008-04-21
CY1107236T1 (el)	2012-05-23
EP1276738A1 (en)	2003-01-22
AU2001281487A1 (en)	2001-10-03
DE60131844T2 (de)	2008-11-27
CA2401241A1 (en)	2001-09-27
KR20020093848A (ko)	2002-12-16
CN1247567C (zh)	2006-03-29
ATE380806T1 (de)	2007-12-15
CN1419552A (zh)	2003-05-21
US20030187004A1 (en)	2003-10-02
CA2401241C (en)	2011-11-29
US6844335B2 (en)	2005-01-18
CN1891220A (zh)	2007-01-10
KR100820543B1 (ko)	2008-04-07
US7378413B2 (en)	2008-05-27
PT1276738E (pt)	2008-02-28

Publication	Publication Date	Title
PT1276738E (pt)	2008-02-28	Derivados de 2-amino-3-(alquil)-pirimidona como inibidores de gsk3.beta.
NL300242I1 (nl)	2006-12-01	Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
SI1686119T1 (sl)	2009-12-31	Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
NO20021239D0 (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
PT1181017E (pt)	2003-06-30	Inibidores de metaloproteases
ZA200108016B (en)	2003-03-26	Pyrazolobenzodiazephines as CDK2 inhibitors.
NO20021833L (no)	2002-04-18	Utkastanordning for innsats
TR200000520A3 (tr)	2001-06-21	4-Fenil-piridin türevleri.
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
DE69906311D1 (de)	2003-04-30	Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20016060D0 (no)	2001-12-12	Kassett for matvarer
PT1171440E (pt)	2004-07-30	3-ciano-¬1,7\|,¬1,5\|, e ¬1,8\|-naftiridinas substituidas inibidoras de tirosina quinases
MA26775A1 (fr)	2004-12-20	Inhibiteurs de metalloproteases dihetero substituees.
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
MXPA03005673A (es)	2003-10-06	Inhibidores de 8-arilquinolin-fosfodiesterasa-4-substituidos.
MXPA00011504A (es)	2003-12-12	Derivados heterociclicos sustituidos.
DK1222193T3 (da)	2003-12-01	Imidazolderivater som phosphodiesterase VII-inhibitorer
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
AU7957000A (en)	2001-05-08	Cyclooxygenase-2 expression inhibitors
IL170468A (en)	2010-12-30	Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
ATE264308T1 (de)	2004-04-15	Aminoalkyl-3,4-dihydrochinolin-derivate als no synthase inhibitoren
ES1043040Y (es)	2000-04-01	Envoltorio para flexometros.
IT1307225B1 (it)	2001-10-30	Sostanza per verruche.
IT1310459B1 (it)	2002-02-18	Tramoggia per sigarette.